tradingkey.logo

India's Cipla extends losses on trimming FY26 margin outlook

ReutersOct 31, 2025 4:38 AM

Cipla CIPL.NS drops ~2% to 1,514.30 rupees; had lost 2.6% in last session

On analyst call, India's no. 3 drugmaker lowers FY26 EBITDA margin outlook, citing declining contribution from generic Revlimid, higher R&D costs

CLSA sees tepid H2 for co, almost negligible contribution from gRevlimid

On Thursday, Cipla beat Q2 profit view, announced CEO rejig

Stock rated "buy" on avg; median PT is 1,720 rupees, per data compiled by LSEG

YTD, CIPL gains 0.9%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI